在新诊断的成人急性淋巴细胞白血病患者中，使用聚乙二醇化 asparaginase 进行强化治疗期间的 asparaginase 活性。
Asparaginase activities during intensified treatment with pegylated asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia.
机构信息
Department of Pediatric Hematology and Oncology, University Children's Hospital of Muenster, Muenster, Germany.
Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
出版信息
Leuk Lymphoma. 2020 Jan;61(1):138-145. doi: 10.1080/10428194.2019.1658099. Epub 2019 Sep 3.
The GMALL07/2003 protocol introduced pegylated asparaginase (PEG-ASNase) frontline for adults with acute lymphoblastic leukemia (ALL). PEG-ASNase (500 U/m, 1000 U/m, or 2000 U/m) was given once in induction and as part of three HD-MTX/PEG-ASNase cycles with two PEG-ASNase doses every other week in consolidation. PEG-ASNase activities were monitored in 1363 serum samples from 304 ALL patients. The overall rate of silent inactivation was low (5%) and did not differ between induction and consolidation. The successful targeting of PEG-ASNase activities ≥100 U/L depended on protocol and dose. Overall PEG-ASNase activities were higher during consolidation compared to induction. To target PEG-ASNase activities ≥100 U/L for 14 day with a single dose in induction, 2000 U/m was more preferable than 1000 U/m or 500 U/m. During consolidation with two administrations every other week, 1000 U/m and 2000 U/m were similarly effective in sustaining PEG-ASNase ≥100 U/L activities over 14 days.
GMALL07/2003 方案将聚乙二醇化天冬酰胺酶（PEG-ASNase）引入急性淋巴细胞白血病（ALL）成人患者的一线治疗。PEG-ASNase（500 U/m、1000 U/m 或 2000 U/m）在诱导期单次给予，并在强化期进行三个 HD-MTX/PEG-ASNase 周期，每两周给予两次，每次给予 2 剂 PEG-ASNase。在 304 例 ALL 患者的 1363 份血清样本中监测了 PEG-ASNase 活性。总的沉默失活率较低（5%），且在诱导期和强化期之间没有差异。成功靶向 PEG-ASNase 活性≥100 U/L 取决于方案和剂量。与诱导期相比，强化期的 PEG-ASNase 活性总体更高。为了在诱导期单次给予时使 PEG-ASNase 活性≥100 U/L 持续 14 天，2000 U/m 比 1000 U/m 或 500 U/m 更可取。在强化期每两周给予两次时，1000 U/m 和 2000 U/m 在维持 PEG-ASNase≥100 U/L 活性超过 14 天方面同样有效。
Zotero 插件